- Biofarma Group acquired 70% of EuroPharma Alliance, adding a dietary-supplement manufacturing platform in Poland.
- Founder Piotr Jandziak retains 30%, while the Rzeplin plant brings five production formats plus in-house development and regulatory teams.
Biofarma Group, a Mereto di Tomba, Italy-based contract manufacturer of health nutrition, medical devices and cosmetics, said Nov. 9 that it completed the acquisition of 70% of EuroPharma Alliance, a Polish dietary-supplement CDMO. Founder Piotr Jandziak retains 30% and will continue working with the group.
EuroPharma operates a plant in Rzeplin, Poland, producing softgels, tablets, hard capsules, powders and liquids. The business also provides formulation, regulatory support and packaging, giving Biofarma a local platform that can take supplement programs from product development through finished-goods production.
Biofarma drew €30 million under its existing €135 million revolving credit facility. The company said the proceeds will finance the acquisition, capital expenditure and general corporate purposes, so the draw does not disclose the EuroPharma purchase price. The transaction expands a contract manufacturing network that now spans nine sites.
The deal follows Biofarma’s September acquisition of EmergoPharm, another Polish nutraceutical producer. Biofarma said the two businesses form a Central and Eastern European development and production hub, combining EuroPharma’s formats with EmergoPharm’s liquid products and direct-to-consumer channels. The company did not disclose EuroPharma’s revenue, capacity or transaction valuation.
Alberto Urli, CEO of Biofarma Group, said the Polish platform broadens the services available to regional brands:
“With a manufacturing platform in Poland, we can now combine agile development with local production, offering clients in the region a complete service.”
Alberto Urli, CEO, Biofarma Group
